Page 66 - Demo

49. PY W. A Pilot Surgical Trial To Evaluate EarlyImmunologic Pharmacodynamic ParametersFor The PD-1 Checkpoint Inhibitor,Pembrolizumab (MK-3475), In Patients WithSurgically Accessible Recurrent/ProgressiveGlioblastoma 2022 [Available from:https://clinicaltrials.gov/study/NCT02852655 50. Phase II Study of Pembrolizumab (MK-3475) Withand Without Bevacizumab for RecurrentGlioblastoma 2020 [Available from:https://clinicaltrials.gov/study/NCT02337491 51. Institute HLMCCaR. A Phase I Trial ofPembrolizumab and Vorinostat CombinedWith Temozolomide and Radiation Therapy forNewly Diagnosed Glioblastoma 2023[Available from:https://clinicaltrials.gov/study/NCT03426891.52. DNAtrix I. A Phase II, Multi-center, Open-labelStudy of a Conditionally ReplicativeAdenovirus (DNX-2401) With Pembrolizumab(KEYTRUDA%u00ae) for Recurrent Glioblastoma orGliosarcoma (CAPTIVE/KEYNOTE-192) 2021[Available from:https://clinicaltrials.gov/study/NCT02798406 53. National-Institute-of-Neurological-DisordersStroke-NINDS). Cytokine Microdialysis For RealTime Immune Monitoring in GlioblastomaPatients Undergoing Checkpoint Blockade2023 [Available from:https://clinicaltrials.gov/study/NCT03493932 54. Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H.Current Immunotherapies for GlioblastomaMultiforme. Front Immunol. 2020;11:603911.55. Lesniak M. Neural Stem Cell Oncolytic AdenoviralVirotherapy of Newly Diagnosed MalignantGlioma 2022 [Available from:https://clinicaltrials.gov/study/NCT03072134 56. Oncology II. Phase Ib Study of OncolyticPolio/Rhinovirus Recombinant AgainstRecurrent Malignant Glioma in Children 2024[Available from:https://clinicaltrials.gov/study/NCT03043391 57. Oncolytics-Biotech. A Phase I/II Clinical Trial toEvaluate Dose Limiting Toxicity and Efficacyof Intralesional Administration of REOLYSIN%u00aefor the Treatment of Patients WithHistologically Confirmed Recurrent MalignantGliomas 2014 [Available from:https://clinicaltrials.gov/study/NCT00528684 41. AVeRT: Anti-PD-1 Monoclonal Antibody(Nivolumab) in Combination With DCVaccines for the Treatment of RecurrentGrade III and Grade IV Brain Tumors 2020[Available from:https://clinicaltrials.gov/study/NCT02529072.42. Northwestern-University. A Phase II, OpenLabel, Clinical Trial Of Pre-Surgical andAdjuvant Treatment of Recurrent MalignantGlioma With Tremelimumab and Durvalumab(MEDI4736) Alone and in Combination toDetermine Immunologic Changes FromTreatment 2022 [Available from:https://clinicaltrials.gov/study/NCT02794883 43. Sidney-Kimmel-Comprehensive-Cancer-CenterJohnsHopkins. A Phase I Trial of Anti-LAG-3or Anti-CD137 Alone and in Combination WithAnti-PD-1 in Patients With Recurrent GBM2023 [Available from:https://clinicaltrials.gov/study/NCT02658981 44. (NCI) N-C-I. Phase I Study of Ipilimumab,Nivolumab, and the Combination in PatientsWith Newly Diagnosed Glioblastoma 2023[Available from:https://clinicaltrials.gov/study/NCT02311920 45. Clinica-Universidad-Navarra. Phase II Study ofNeoadjuvant Nivolumab in Patients WithGlioblastoma Multiforme 2017 [Availablefrom: https://clinicaltrials.gov/study/NCT02550249.46. Squibb. B-M. A Randomized Phase 3 Open LabelStudy of Nivolumab vs Temozolomide Each inCombination With Radiation Therapy inNewly Diagnosed Adult Subjects WithUnmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase)Glioblastoma (CheckMate 498: CHECKpointPathway and Nivolumab Clinical TrialEvaluation 498) 2023 [Available from:https://clinicaltrials.gov/study/NCT02617589 47. NYU-Langone-Health. A Phase II, Open-label,Single Arm Trial of Nivolumab, Ipilimumab,and Short course Radiotherapy in Adults WithNewly Diagnosed, MGMT UnmethylatedGlioblastoma 2022 [Available from:https://clinicaltrials.gov/study/NCT0336771548. Incyte-Corporation. A Phase 1/2 Study of the64ANALESRANFwww.analesranf.comSafety, Tolerability, and Efficacy ofEpacadostat Administered in CombinationWith Nivolumab in Select Advanced Cancers (ECHO-204) 2023 [Available from: https://clinicaltrials.gov/study/NCT02327078An. R. Acad. Farm.vol. 91. n%u00ba1 (2025) %u00b7 pp. 45-66Immunotherapy against glioblastoma multiformeLuc%u00eda S%u00e1nchez Prieto y %u00c1ngel Cuesta Mart%u00ednez